Corvus Pharmaceuticals released positive Cohort 4 data for soquelitinib, an oral ITK inhibitor, in moderate-to-severe atopic dermatitis.
In this 8-week, randomized, placebo-controlled extension:
Soquelitinib 200 mg BID reduced EASI score by 72% vs 40% on placebo.
75% reached EASI-75, 25% EASI-90, 33% IGA 0/1 (clear/almost clear).
The upstream T-cell approach reduced Th2/Th17 cytokines and boosted regulatory T cells, offering a novel immunotherapy angle distinct from current biologics.
Early data suggest soquelitinib could become a potent, convenient oral option for refractory AD.
There is ongoing anticipation for OX40/OX40L inhibitors (e.g., rocatinlimab, amlitelimab) as a new therapeutic class for AD.
There is a research shift toward upstream immune modulation (e.g., T-cell targeting via OX40L or ITK) for potentially more durable or convenient AD control, with several candidates advancing toward regulatory filings.
Atopic dermatitis maintenance (click to enlarge the image).